Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 7/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 5/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.39 |
| ▸ | SCD | O00767 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.35 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.35 |
| ▸ | PRKCB | P05771 | 1/20 | 0.35 |
| ▸ | CDK1 | P06493 | 1/20 | 0.35 |
| ▸ | LYN | P07948 | 1/20 | 0.35 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.35 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23827383 | 0.94 | SCD (0.39) | MAPTTDP1NPSR1KDM4ESCD | |
| SCHEMBL23827381 | 0.94 | SCD (0.39) | MAPTTDP1NPSR1KDM4ESCD | |
| SCHEMBL18991515 | 0.89 | MMP2 (0.38) | PDPK1CCNB2PRKCBCDK1LYN | |
| SCHEMBL29360136 | 0.89 | MMP2 (0.38) | PDPK1CCNB2PRKCBCDK1LYN | |
| SCHEMBL18991513 | 0.89 | MMP2 (0.38) | PDPK1CCNB2PRKCBCDK1LYN | |
| SCHEMBL23827380 | 0.88 | SCD (0.43) | MAPTTDP1NPSR1KDM4ESCD | |
| SCHEMBL23827382 | 0.88 | SCD (0.43) | MAPTTDP1NPSR1KDM4ESCD | |
| SCHEMBL22013230 | 0.85 | MAPT (0.41) | MAPTTDP1NPSR1KDM4ESCD | |
| SCHEMBL23838022 | 0.85 | MAPT (0.41) | MAPTTDP1NPSR1KDM4ESCD | |
| SCHEMBL20566016 | 0.83 | MMP2 (0.39) | PDPK1CCNB2PRKCBCDK1LYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220002288-A1 | MONOBACTAM COMPOUNDS AND USE THEREFOR | NANJING SANHOME PHARMACEUTICAL CO., LTD. (CN) | 2022-01-06 | — | — | US | disclosed |
| EP-3882246-A1 | MONOBACTAM COMPOUNDS AND USE THEREFOR | Nanjing Sanhome Pharmaceutical Co., Ltd. (CN) | 2021-09-22 | — | — | EP | disclosed |
| WO-2020098635-A1 | MONOBACTAM COMPOUNDS AND USE THEREFOR | 南京圣和药业股份有限公司 | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220002288-A1 | MONOBACTAM COMPOUNDS AND USE THEREFOR | BPGM, IL1B, WEE1 | MAPT 1841/4885TDP1 3885/4885NPSR1 3614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.